Table 1. Prognostic effects of the E2F score in resected lung adenocarcinoma patients who did not receive adjuvant chemotherapy.
| Low E2F | High E2F | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall survival | N | Median survival | 5-year Survival rate (%) |
N | Median survival | 5-year Survival rate (%) |
Log-rank test p-value |
HR** (95% CI) High vs. Low |
||||||||
| Fresh Frozen: Individual cohorts | ||||||||||||||||
| MLOS[33] All stages (N=300) | 156 | NR* | 73 | 144 | 40.4 | 33 | <0.001 | 2.58 (1.59, 4.17) | ||||||||
| MCLA[34] All stages (N=233) | 119 | NR | 72 | 114 | NR | 50 | <0.001 | 2.32 (1.48, 3.64) | ||||||||
| TCGA[36] All stages (N=436) | 185 | 53.3 | 35 | 251 | 35.8 | 29 | 0.008 | 1.74 (1.15, 2.64) | ||||||||
| JBR10.AD[22] All stages (N=32) | 21 | NR | 71 | 11 | 36.4 | 22 | 0.007 | 3.9 (1.35, 11.32) | ||||||||
| LCBRN All stages (N=64) | 31 | NR | 89*** | 33 | 40.8 | 69*** | 0.028 | 4.74 (1.02, 21.97) | ||||||||
| Combined FF cohorts (MLOS, MCLA, TCGA, LCBRN, JBR10.AD) | ||||||||||||||||
| All Stages (N=1065) | 512 | NR | 64 | 553 | 42.9 | 41 | <0.001 | 2.38 (1.86, 3.05) | ||||||||
| Stage I (N=696) | 387 | NR | 75 | 309 | NR | 54 | <0.001 | 2.22 (1.55, 3.17) | ||||||||
| Stage II (N=202) | 70 | 50 | 31 | 132 | 28.8 | 29 | 0.061 | 1.58 (0.97, 2.55) | ||||||||
| Stage III/IV (N=159) | 50 | 35.4 | 24 | 109 | 20.8 | 18 | 0.053 | 1.65 (0.99, 2.75) | ||||||||
|
FFPE: Individual cohorts | ||||||||||||||||
| MLCom All stages (N=101) | 55 | 75.5 | 62 | 46 | 42.6 | 50 | 0.041 | 1.87 (1.02, 3.44) | ||||||||
| NATCH All stages (N=40) | 13 | 81.5 | 69 | 27 | 25.1 | 20 | 0.014 | 3.26 (1.21, 8.78) | ||||||||
| Combined FFPE cohorts (MLCom and NATCH) | ||||||||||||||||
| All Stages (N=141) | 68 | 81.5 | 64 | 73 | 33 | 38 | <0.001 | 2.29 (1.39, 3.76) | ||||||||
| Stage I (N=94) | 52 | NR | 75 | 42 | NR | 57 | 0.0495 | 2.04 (0.99, 4.21) | ||||||||
| Stage II (N=19) | 6 | 64.7 | 62 | 13 | 16.1 | 23 | 0.0501 | 3.54 (0.93, 13.4) | ||||||||
| Stage III/IV (N=28) | 10 | 25 | 13 | 18 | 19.6 | 7 | 0.357 | 1.51 (0.63, 3.6) | ||||||||
NR*: median survival time not reached within the study
HR**: hazard ratio
*** indicates 3-year survival cutoff since 5-year survival rate was not estimated due to short follow-up
Significant P values are in bold text